Biotech Values

[DewDiligence]

More on “creative” (translation: low) drug prices in Europe:

http://www.reuters.com/article/2012/10/24/us-pharmaceuticals-europe-pricing-idUSBRE89N0GQ20121024

Many of today's complicated pricing arrangements have their origins in pioneering work by Britain's National Institute for Health and Clinical Excellence (NICE), which was set up in 1999 to systematically assess the cost-effectiveness of new drugs.

... Cancer drugs are a major focus, reflecting the dilemma posed by costly new treatments that may help some patients but often only extend life by only a few months.